Literature DB >> 12614247

The number of lymph nodes examined and staging accuracy in renal cell carcinoma.

C Terrone1, S Guercio, S De Luca, M Poggio, E Castelli, C Scoffone, R Tarabuzzi, R M Scarpa, D Fontana, S Rocca Rossetti.   

Abstract

OBJECTIVE: To determine the number of lymph nodes that need to be examined to accurately stage the pN variable in patients undergoing radical nephrectomy (RN) for renal cell carcinoma (RCC). PATIENTS AND METHODS: We reviewed the operative and pathology reports of 725 patients with RCC submitted for RN. All tumours were classified using the fifth edition of the Tumour-Nodes-Metastasis classification. For each patient the number of lymph nodes removed was recorded. The patients were divided into five different groups according to the number of nodes removed, i.e. group 1, 1-4; group 2, 5-8; group 3, 9-12; group 4, 13-16; and group 5, >or= 17. We evaluated the factors that affected the number of lymph nodes removed with nodal dissection and the variables that influenced the incidence of nodal involvement.
RESULTS: Lymphadenectomy was performed in 608 patients (83.8%); in these patients the rate of lymph node metastases was 13.6%. The median (range) number of nodes removed was 9 (1-43); there was a statistically significant correlation between the number of nodes removed and the percentage of nodal involvement (r = 0.6; P < 0.01). The rate of pN+ was significantly higher in the patients with >or= 13 than in those with < 13 nodes examined (20.8% vs 10.2%; P < 0.001). For organ-confined and locally advanced tumours there was a statistically significant difference in the pN+ rate between patients with < 13 or >or= 13 nodes examined (3.4% vs 10.5%, and 19.7% vs. 32.2%, respectively).
CONCLUSIONS: The proportion of tumours classified as pN+ increased with the number of lymph nodes examined. In RCC,> 12 lymph nodes need to be assessed for optimal staging.

Entities:  

Mesh:

Year:  2003        PMID: 12614247     DOI: 10.1046/j.1464-410x.2003.04017.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  29 in total

1.  Management of kidney cancer: canadian kidney cancer forum consensus update 2011.

Authors:  Mas Jewett; A Finelli; C Kollmannsberger; L Wood; L Legere; J Basiuk; C Canil; D Heng; N Reaume; S Tanguay; M Atkins; G Bjarnason; J Dancey; M Evans; N Fleshner; M Haider; A Kapoor; R Uzzo; D Maskens; D Soulieres; G Yousef; N Basappa; N Bendali; P Black; N Blais; I Cagiannos; M Care; R Chow; H Chung; P Czaykowski; D Derosa; K Durrant; S Ellard; G Farquharson; C Filion-Brulotte; J Gingerich; L Godbout; R Grant; W Hamilton; W Kassouf; G Kurban; K Lane; Jb Lattouf; D Lau; M Leveridge; J McCarthy; R Moore; S North; P O'brien; E Pituskin; P Racine; R Rendon; A So; S Sridhar; K Stubbs; Z Su; L Taylor; T Udall; P Venner; W Vogel; S Yap; P Yau; M Cooper; N Giroux; D Miron; D Mosher; K Ross; J Willacy
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

Review 2.  [Lymph node dissection in patients with renal cell carcinoma].

Authors:  T Ebert; D Schnell; L Weissbach
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

3.  Further Classification for Node-Positive Gastric Neuroendocrine Neoplasms.

Authors:  Linda M Pak; Tingsong Yang; Jiping Wang
Journal:  J Gastrointest Surg       Date:  2018-06-27       Impact factor: 3.452

4.  Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma.

Authors:  Malte Rieken; Stephen A Boorjian; Luis A Kluth; Umberto Capitanio; Alberto Briganti; R Houston Thompson; Bradley C Leibovich; Laura-Maria Krabbe; Vitaly Margulis; Jay D Raman; Mikhail Regelman; Pierre I Karakiewicz; Morgan Rouprêt; Mohammad Abufaraj; Beat Foerster; Mithat Gönen; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-11-07       Impact factor: 4.226

5. 

Authors: 
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

6.  Analysis of lymph node dissection in patients with ≥7-cm renal tumors.

Authors:  Michael A Feuerstein; Matthew Kent; Wassim M Bazzi; Melanie Bernstein; Paul Russo
Journal:  World J Urol       Date:  2014-01-09       Impact factor: 4.226

7.  [Organ and kidney function preservation in renal cell carcinoma].

Authors:  M Schenck; R Eder; H Rübben; C Niedworok; S Tschirdewahn
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

Review 8.  The rationale and the role of lymph node dissection in renal cell carcinoma.

Authors:  Umberto Capitanio; Bradley C Leibovich
Journal:  World J Urol       Date:  2016-06-30       Impact factor: 4.226

9.  Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement.

Authors: 
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

10.  Staging of renal cell carcinoma: Current concepts.

Authors:  John S Lam; Tobias Klatte; Alberto Breda
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.